Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews
Li D, Farrell JJ, Mez J, Martin ER, Bush WS, Ruiz A, Boada M, de Rojas I, Mayeux R, Haines JL, Vance MAP, Wang LS, et al.. Alzheimer's & Dementia, 2023-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Most Alzheimer's disease (AD) loci have been discovered in individuals with European ancestry (EA). Methods We applied principal component analysis using Gaussian mixture models and an Ashkenazi Jewish (AJ) reference genome-wide association study (GWAS) data set to identify Ashkenazi Jews ascertained in GWAS (n = 42,682), whole genome sequencing (WGS, n = 16,815), and whole exome sequencing (WES, n = 20,504) data sets. The association of AD was tested genome wide (GW) in the GWAS and WGS data sets and exome wide (EW) in all three data sets (EW). Gene-based analyses were performed using aggregated rare variants. Results In addition to apolipoprotein E (APOE), GW analyses (1355 cases and 1661 controls) revealed associations with TREM2 R47H (p = 9.66 × 10 -9 ), rs541586606 near RAB3B (p = 5.01 × 10 -8 ), and rs760573036 between SPOCK3 and ANXA10 (p = 6.32 × 10 -8 ). In EW analyses (1504 cases and 2047 controls), study-wide significant association was observed with rs1003710 near SMAP2 (p = 1.91 × 10 -7 ). A significant gene-based association was identified with GIPR (p = 7.34 × 10 -7 ). Discussion Our results highlight the efficacy of founder populations for AD genetic studies.
What this study adds
Evidence grade: Moderate
This is a case-control study. In people of Ashkenazi Jewish ancestry, this study confirmed known Alzheimer's genes like APOE and TREM2 and found additional associations near RAB3B, SPOCK3, ANXA10, SMAP2, and GIPR. These results show that studying founder populations can help uncover genetic risk factors for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Li, D., Farrell, J. J., Mez, J., Martin, E. R., Bush, W. S., Ruiz, A., et al. (2023). Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13117
Vancouver
Li D, Farrell JJ, Mez J, Martin ER, Bush WS, Ruiz A, et al. Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews. Alzheimer's & Dementia. 2023. doi:10.1002/alz.13117. PMID: 37260021.
BibTeX
@article{li2023-37260021,
author = {Li, D. and Farrell, J. J. and Mez, J. and Martin, E. R. and Bush, W. S. and Ruiz, A. and Boada, M. and de Rojas, I. and Mayeux, R. and Haines, J. L. and Vance, M. A. P. and Wang, L. S. and others},
title = {{Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews}},
journal = {Alzheimer's \& Dementia},
year = {2023},
doi = {10.1002/alz.13117},
pmid = {37260021},
url = {https://doi.org/10.1002/alz.13117}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results In addition to apolipoprotein E (APOE), GW analyses (1355 cases and 1661 controls) revealed associations with TREM2 R47H (p = 9.66 × 10 -9 ), rs541586606 near RAB3B (p = 5.01 × 10 -8 ), and rs760573036 between SPOCK3 and ANXA10 (p = 6.32 × 10 -8 ).
- In EW analyses (1504 cases and 2047 controls), study-wide significant association was observed with rs1003710 near SMAP2 (p = 1.91 × 10 -7 ).
- A significant gene-based association was identified with GIPR (p = 7.34 × 10 -7 ).
- Discussion Our results highlight the efficacy of founder populations for AD genetic studies.
Why it matters
In people of Ashkenazi Jewish ancestry, this study confirmed known Alzheimer's genes like APOE and TREM2 and found additional associations near RAB3B, SPOCK3, ANXA10, SMAP2, and GIPR. These results show that studying founder populations can help uncover genetic risk factors for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcase-control
- Evidence strengthModerate
Limitations
Sample size is small compared with other AD GWAS; stringent ancestry boundaries excluded some individuals with substantial Ashkenazi ancestry; infrequent variants may have been poorly imputed in smaller cohorts; part of the data came from exome sequencing, reducing the sample for genome-wide analyses.
How this study scored 52/100
Published in a leading specialty journal, and it is a case-control study. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 51 of the 98 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Lindsay A. Farrer: h-index 119 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37260021) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 51 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 98 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.